Merck’s enlicitide shows superior cholesterol reduction vs rivals

Enlicitide produced a 64.6% LDL-C reduction from baseline at 8 weeks and outperformed bempedoic acid (56.7% delta), ezetimibe (36.0%) and their combo (28.1%); 78.2% of enlicitide patients achieved ≥50% LDL-C reduction with LDL-C <55 mg/dL and no serious drug-related adverse events were reported. The FDA selected enlicitide for the Commissioner’s National Priority Voucher (Dec 2025) and the CORALreef Outcomes trial has enrolled >14,500 participants. Separately, Merck launched a $53/share cash bid for Terns Pharmaceuticals, prompting analyst rating moves, and the stock has risen ~45% over six months while being flagged as undervalued by InvestingPro.

Analysis

Merck’s positive lipid program read-through is less about a single percent reduction and more about the strategic shift from biologic injections to an orally dosed PCSK9-class therapy. That change lowers manufacturing complexity and distribution friction, which should accelerate adoption in primary-care settings and emerging markets where injectable specialist access and cold-chain logistics are constraints. This dynamic creates a multi-year earnings kicker through both volume growth and margin expansion, but it is also a direct demand shock to incumbent injectable specialists — expect pricing pressure and accelerated discounting from players who monetize through high-margin clinic-administered products.

Near-term value will be driven by regulatory milestones, commercialization planning and the optics of integration activity rather than final outcomes data, which remains a multi-year binary. The biggest reversal risks are a late-stage safety signal, payer pushback on price, or adverse trial readouts in the large outcomes program; any of these would quickly compress the elevated multiple the market has already applied. Separately, the announced bolt-on M&A increases execution and regulatory risk while modestly de-risking the hematology line — an acquisition can be value-accretive but also amplifies short-term volatility around approvals and filings.

Second-order winners include specialty generic manufacturers and contract API/solid-dose CMOs that can scale oral small-molecule production cheaply; losers include infusion center volumes and the distribution franchisees of injectable biologics. For hedge funds, the story is most actionable as a relative-value and event-driven play: capture upside from regulatory/commercial progress while protecting against binary downside from trial or payer outcomes, and consider merger-arbitrage on the small-cap target if the spread is attractive.

Key Decisions for Investors

• Buy a defined-risk MRK call spread (12–15 month): buy MRK 5% OTM call / sell MRK 30% OTM call to express upside from regulatory/commercial progress while capping cost. Timeframe: 9–15 months. Risk/Reward: limited downside = premium paid; target 2:1+ upside if positive catalysts (approvals, favorable commercial launch signals).
• Relative-value pair (6–18 months): go long MRK equity and short AMGN or NVS (equal dollar) to isolate upside from oral PCSK9 optionality versus incumbents in injected biologics. Risk/Reward: reduces market beta; wins if MRK captures share or rerates versus peers; primary risk is sector rotation back to biologics providers.
• Merger-arb on TERN (event-driven, short horizon): if TERN trades meaningfully below the announced deal consideration (>1–3% spread), buy the equity and hedge with a small short on biotech index exposure. Timeframe: 1–6 months to close. Risk/Reward: capture spread as carry with deal risk (regulatory/financing); use position size limits and legal/regulatory monitoring.
• Hedge protection (near-term, 3–6 months): buy MRK puts or collar existing MRK longs around key near-term filings/PD meetings to guard against binary downside from safety or payer pushback. Risk/Reward: pays insurance premium to limit drawdowns around high-impact events.